Health
GC Pharma sticks to plasma therapy study despite global trial failures – Korea Biomedical Review
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing…
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing results in phase 3 clinical trials.
Takeda, one of the co-leaders of the CoVig-19 Plasma Alliance, said Wednesday that the group has completed the phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trials and decided to end the year-long collaboration as it did not meet the endpoint in the study.
…
-
Noosa News15 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News13 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News23 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common